The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) injection, the first and only ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

A compound that showed early promise in the treatment of Parkinson's disease in fruit flies has also shown neuroprotective ...

A new study published in the Journal of Medical Internet Research has found that regular participation in dance classes can ...

Onapgo is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with advanced disease ...

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.